[go: up one dir, main page]

PE20140222A1 - Vacunas basadas en omv contra infecciones por burkholderia - Google Patents

Vacunas basadas en omv contra infecciones por burkholderia

Info

Publication number
PE20140222A1
PE20140222A1 PE2013001551A PE2013001551A PE20140222A1 PE 20140222 A1 PE20140222 A1 PE 20140222A1 PE 2013001551 A PE2013001551 A PE 2013001551A PE 2013001551 A PE2013001551 A PE 2013001551A PE 20140222 A1 PE20140222 A1 PE 20140222A1
Authority
PE
Peru
Prior art keywords
external membrane
vesicules
omv
burkholderia
supernadant
Prior art date
Application number
PE2013001551A
Other languages
English (en)
Inventor
Lisa A Morici
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46507675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of PE20140222A1 publication Critical patent/PE20140222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE COMPRENDE: A) VESICULAS DE MEMBRANA EXTERNA (OMV) QUE DERIVAN DE UNA BACTERIA GRAM NEGATIVA TAL COMO BURKHOLDERIA PSEUDOMALLEI Y/O BURKHOLDERIA MALLEI QUE ADEMAS COMPRENDEN LIPOPOLISACARIDO (LPS) Y POLISACARIDO CAPSULAR (CPS); Y B) UN ADYUVANTE TAL COMO OLIGODESOXINUCLEOTIDOS CpG METILADOS (ODN CpG), HIDROXIDO DE ALUMINIO, MPL-MONOFOSFATO LIPIDO A, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE DICHA COMPOSICION QUE COMPRENDE: i) CRECIMIENTO DEL CULTIVO DE BACTERIAS GRAM NEGATIVAS; ii) SOMETER DICHO CULTIVO A CENTRIFUGACION, OBTENIENDO UN PELET CELULAR Y UNA FRACCION DE SOBRENADANTE; iii) RECOLECTAR LAS VESICULAS DE MEMBRANA EXTERNA A PARTIR DE LA FRACCION DE SOBRENADANTE; iv) PURIFICAR LAS VESICULAS DE MEMBRANA EXTERNA POR CENTRIFUGACION EN GRADIENTE; Y v) RECOLECTAR LAS VESICULAS DE MEMBRANA EXTERNA QUE SE PURIFICARON. DICHA COMPOSICION INMUNOGENICA ES UNA VACUNA QUE PROVEE PROTECCION CONTRA INFECCIONES CAUSADAS POR BURKHOLDERIA
PE2013001551A 2011-01-12 2012-01-12 Vacunas basadas en omv contra infecciones por burkholderia PE20140222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432040P 2011-01-12 2011-01-12

Publications (1)

Publication Number Publication Date
PE20140222A1 true PE20140222A1 (es) 2014-03-12

Family

ID=46507675

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001551A PE20140222A1 (es) 2011-01-12 2012-01-12 Vacunas basadas en omv contra infecciones por burkholderia

Country Status (9)

Country Link
US (1) US20140004178A1 (es)
AU (1) AU2012205498A1 (es)
CO (1) CO6751260A2 (es)
GB (1) GB2518813A (es)
MX (1) MX2013008071A (es)
PE (1) PE20140222A1 (es)
PH (1) PH12013501452A1 (es)
SG (1) SG191940A1 (es)
WO (1) WO2012097185A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013360738B2 (en) * 2012-12-18 2018-08-30 University College Dublin, National University Of Ireland, Dublin A vaccine for treatment or prevention of Burkholderia infection in a mammal
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
WO2015155178A1 (en) * 2014-04-07 2015-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for producing outer membrane vesicles
WO2018031832A1 (en) * 2016-08-12 2018-02-15 The Procter & Gamble Company Method and apparatus for assembling absorbent articles
BR112019019440A2 (pt) * 2017-03-31 2020-04-14 Indian Council Medical Res vacina contra febre tifoide a base de vesículas de membrana externa de duas cepas diferentes de espécies de salmonella tifoide
US11542467B2 (en) 2017-12-04 2023-01-03 Intravacc B.V. Process for producing outer membrane vesicles
US11534486B2 (en) 2018-04-10 2022-12-27 Administrators Of The Tulane Educational Fund Burkholderia pseudomallei complex outer membrane vesicles as adjuvants
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
CN112410240B (zh) * 2019-08-22 2022-10-18 四川大学 铜绿假单胞菌膜囊泡及其制备方法与应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111440748A (zh) * 2020-05-15 2020-07-24 黑龙江八一农垦大学 一种分离、提纯及鉴定坏死杆菌外膜囊泡的方法
WO2022147238A1 (en) * 2020-12-30 2022-07-07 University Of Hawaii Burkholderia vaccines and therapeutics
CN119563017A (zh) * 2022-05-27 2025-03-04 浦项工科大学校产学协力团 用于构建源自革兰氏阴性菌外膜的纳米囊泡的方法及其用途
CN119139463B (zh) * 2024-11-18 2025-04-01 苏州大学附属儿童医院 一种基于卡介苗BCG的OMVs训练免疫诱导剂在制备脓毒症免疫治疗药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028215A1 (en) * 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB2441094B (en) * 2005-05-19 2010-11-03 Edward Jenner Inst For Vaccine Methods for treatment and prevention of infection
GB0615635D0 (en) * 2006-08-07 2006-09-13 Secr Defence Immunogenic proteins and uses thereof
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines

Also Published As

Publication number Publication date
AU2012205498A1 (en) 2013-08-01
WO2012097185A2 (en) 2012-07-19
PH12013501452A1 (en) 2018-03-21
WO2012097185A3 (en) 2012-10-11
GB2518813A (en) 2015-04-08
US20140004178A1 (en) 2014-01-02
CO6751260A2 (es) 2013-09-16
SG191940A1 (en) 2013-08-30
MX2013008071A (es) 2013-09-26

Similar Documents

Publication Publication Date Title
PE20140222A1 (es) Vacunas basadas en omv contra infecciones por burkholderia
AR078253A1 (es) Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
PH12017501445A1 (en) Methods for producing virus for vaccine production
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
EP2765138A3 (en) HIV-1 envelope glycoprotein
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
WO2012140127A3 (en) Method for priming of t cells
MX2019002495A (es) Metodos para producir virus para la produccion de vacunas.
CL2011002852A1 (es) Uso de bacterias del acido lactico probioticas por un tratamiento con calor para la preparacion de composiciones para prevenir o tratar inmunodeficiencias causadas por infecciones bacterianas, virales, fungicas y/o parasitarias.
MX384875B (es) Método para obtener una vacuna de mycoplasma.
CL2008001294A1 (es) Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua.
WO2014009971A3 (en) Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
MX373361B (es) Composiciones inmunológicas que contienen histophilus somni atenuado.
PE20171131A1 (es) Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PE20141264A1 (es) Procedimiento de obtencion de una composicion que contiene factores de crecimiento a partir de un compuesto sanguineo, y composicion obtenible por dicho procedimiento
CO6390040A2 (es) Procedimiento para la producción de vacunas
BR112012016048A2 (pt) "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos".
CL2013002723A1 (es) Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto.
BR112013006515A2 (pt) vacina de combinação, e, método para a fabricação de uma vacina de combinação
MX344544B (es) Vacuna para paludismo en etapa sanguinea.
BR112015015107A2 (pt) método para remover contaminantes bacterianos de solução sacarificada e sistema de fermentação
BR112014014390A2 (pt) levedura recombinante, seus usos, processo para vacinação, oligonucleotídeo, vetor de expressão, e método de produção de uma composição de vacina
ECSP088907A (es) Vacuna en contra de organismos similares a rickettsia
AR085271A1 (es) Procedimiento para la produccion a escala comercial de prrsv

Legal Events

Date Code Title Description
FD Application declared void or lapsed